X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12) 12
female (9) 9
index medicus (9) 9
drug therapy (8) 8
male (8) 8
middle aged (8) 8
aged (7) 7
abridged index medicus (6) 6
heart attacks (6) 6
blood platelets (5) 5
cardiovascular disease (5) 5
cardiovascular diseases (5) 5
double-blind method (5) 5
ischemia (5) 5
patients (5) 5
risk (5) 5
stroke (5) 5
analysis (4) 4
clinical trials (4) 4
medicine, general & internal (4) 4
myocardial infarction (4) 4
prevention (4) 4
treatment outcome (4) 4
acute coronary syndromes (3) 3
aspirin (3) 3
bevacizumab (3) 3
blood pressure (3) 3
cardiac & cardiovascular systems (3) 3
cardiovascular diseases - mortality (3) 3
care and treatment (3) 3
cerebral infarction (3) 3
clopidogrel (3) 3
dosage and administration (3) 3
drug therapy, combination (3) 3
hemorrhage (3) 3
hemorrhage - chemically induced (3) 3
hypertension (3) 3
kaplan-meier estimate (3) 3
life sciences (3) 3
mortality (3) 3
ophthalmology (3) 3
platelet aggregation inhibitors - therapeutic use (3) 3
ranibizumab (3) 3
secondary prevention (3) 3
acute disease (2) 2
aggregation (2) 2
american-college (2) 2
angiogenesis inhibitors - therapeutic use (2) 2
animals (2) 2
antibodies, monoclonal, humanized - therapeutic use (2) 2
arteriosclerosis (2) 2
association task-force (2) 2
atherosclerosis (2) 2
atherosclerosis - drug therapy (2) 2
bleeding (2) 2
brain ischemia (2) 2
cardiology (2) 2
cardiovascular diseases - prevention & control (2) 2
comparative analysis (2) 2
death (2) 2
diabetes (2) 2
disease prevention (2) 2
dose-response relationship (2) 2
drug administration schedule (2) 2
flow (2) 2
fluorescein angiography (2) 2
follow-up studies (2) 2
heart attack (2) 2
heart rate (2) 2
history (2) 2
human health and pathology (2) 2
intracranial hemorrhages (2) 2
intracranial hemorrhages - chemically induced (2) 2
intravitreal injections (2) 2
lactones (2) 2
lactones - therapeutic use (2) 2
macular degeneration (2) 2
management (2) 2
medical imaging (2) 2
myocardial infarction - drug therapy (2) 2
myocardial infarction - therapy (2) 2
myocardial-infarction (2) 2
outcomes (2) 2
peptides - therapeutic use (2) 2
peripheral arterial disease (2) 2
physiological aspects (2) 2
platelet aggregation inhibitors (2) 2
platelet aggregation inhibitors - administration & dosage (2) 2
platelet aggregation inhibitors - adverse effects (2) 2
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (2) 2
prasugrel (2) 2
prospective studies (2) 2
pyridines (2) 2
pyridines - therapeutic use (2) 2
receptor, par-1 (2) 2
receptor, par-1 - antagonists & inhibitors (2) 2
research (2) 2
retreatment (2) 2
risk factors (2) 2
safety (2) 2
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Online Resources - Online (1) 1
Robarts - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
UTL at Downsview - May be requested (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
Victoria University Emmanuel College - Birge Storage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
Patients with myocardial infarction 1 to 3 years previously were assigned to ticagrelor, 90 or 60 mg twice daily, or to placebo, in addition to low-dose... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Life Sciences | Human health and pathology
Journal Article
American Heart Journal, ISSN 0002-8703, 2006, Volume 152, Issue 4, pp. 668 - 675
Journal Article
American Heart Journal, ISSN 0002-8703, 2009, Volume 158, Issue 3, pp. 335 - 341.e3
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2006, Volume 47, Issue 12, pp. 2364 - 2373
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 15, pp. 1404 - 1413
Patients with atherosclerotic vascular disease were randomly assigned to receive the thrombin antagonist vorapaxar or placebo. Vorapaxar reduced the rate of... 
ATOPAXAR | MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | EFFICACY | SAFETY | TOLERABILITY | DOUBLE-BLIND | PRASUGREL | LESSONS | ANTAGONISTS | ASPIRIN | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Risk | Secondary Prevention | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Female | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - therapeutic use | Double-Blind Method | Hemorrhage - epidemiology | Receptor, PAR-1 - antagonists & inhibitors | Kaplan-Meier Estimate | Peripheral Arterial Disease - drug therapy | Stroke - drug therapy | Lactones - adverse effects | Lactones - therapeutic use | Retreatment | Myocardial Infarction - drug therapy | Brain Ischemia - drug therapy | Intracranial Hemorrhages - chemically induced | Intracranial Hemorrhages - epidemiology | Aged | Hemorrhage - chemically induced | Prevention | Drugs | Aggregation | Dose-response relationship (Biochemistry) | Atheroembolism | Blood platelets | Atherosclerosis | Product/Service Evaluations | Dosage and administration | Drug therapy | Myocardial infarction | Cerebral infarction | Stroke | Aspirin | Heart attacks | Proteinase-activated receptor 1 | Thrombin | Hemorrhage | Patients | Bleeding | Disease prevention | Ischemia | Arteriosclerosis | Death | Cardiovascular diseases | Health risk assessment | Computer Science | Medical Imaging
Journal Article